A detailed history of Raymond James Financial Services Advisors, Inc. transactions in United Therapeutics Corp stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 6,429 shares of UTHR stock, worth $2.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,429
Previous 1,385 364.19%
Holding current value
$2.4 Million
Previous $441,000 422.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$311.04 - $363.55 $1.57 Million - $1.83 Million
5,044 Added 364.19%
6,429 $2.3 Million
Q2 2024

Jul 19, 2024

SELL
$228.26 - $319.04 $55,238 - $77,207
-242 Reduced 14.87%
1,385 $441,000
Q1 2024

Apr 22, 2024

SELL
$210.76 - $249.51 $15,596 - $18,463
-74 Reduced 4.35%
1,627 $373,000
Q4 2023

Jan 16, 2024

SELL
$214.88 - $256.94 $138,382 - $165,469
-644 Reduced 27.46%
1,701 $374,000
Q3 2023

Oct 24, 2023

BUY
$211.82 - $248.24 $162,889 - $190,896
769 Added 48.79%
2,345 $529,000
Q2 2023

Jul 25, 2023

BUY
$205.19 - $232.99 $138,913 - $157,734
677 Added 75.31%
1,576 $347,000
Q1 2023

Apr 14, 2023

BUY
$212.99 - $276.17 $11,714 - $15,189
55 Added 6.52%
899 $201,000
Q4 2022

Feb 08, 2023

SELL
$205.95 - $280.43 $417,048 - $567,870
-2,025 Reduced 70.58%
844 $234,000
Q3 2022

Oct 25, 2022

BUY
$203.3 - $244.17 $28,665 - $34,427
141 Added 5.17%
2,869 $601,000
Q2 2022

Aug 12, 2022

BUY
$174.81 - $241.14 $476,881 - $657,829
2,728 New
2,728 $643,000
Q2 2018

Jul 30, 2018

SELL
$101.14 - $118.31 $181,242 - $212,011
-1,792 Closed
0 $0
Q1 2018

Apr 16, 2018

BUY
$107.21 - $151.94 $27,981 - $39,656
261 Added 17.05%
1,792 $201,000
Q4 2017

Feb 09, 2018

BUY
$118.58 - $151.28 $181,545 - $231,609
1,531
1,531 $227,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.